



Ref: JSTL/BOD/BSE/2026-27/May 26

Date: May 29, 2026

To,
The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001

Dear Sir/ Madam,

Unit: Jeevan Scientific Technology Limited (Scrip Code: 538837)

Sub: Outcome of Board Meeting held on 29.05.2026

With reference to the subject cited, this is to inform the exchange that the Board of Directors of Jeevan Scientific Technology Limited at its meeting held on Friday, 29.05.2026 at 12:30 Noon at the registered office of the Company, considered and approved the following:

1. Audited Financial Results (standalone and consolidated) for the quarter and financial year ended 31.03.2026. (**Attached**).
2. Auditors Report (standalone and consolidated) along with declaration of unmodified opinion for the financial year 31.03.2026. (**Attached**).
3. Appointment of M/s. KP & Associates, Chartered Accountants as Internal Auditors of the Company for FY 2026-27. (Details attached as **Annexure I**).
4. Granting of 4,80,000 Stock options to the eligible employees of Company pursuant to JSTL ESOP Scheme 2016. (Details attached as **Annexure II**)
5. Allotment of 1,61,250 Equity Shares of Rs. 10/- each to the eligible employees of the Company who have exercised their Options under the "JSTL- ESOP Scheme 2016".

The details of the shares allotted pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 under ESOS – 2014 are given in **Annexure III** and **Annexure IV** respectively.

The meeting concluded at 02:10 P.M.



This is for the information and records of the Exchange, please.

Thanking You.

Yours faithfully,

For Jeevan Scientific Technology Limited

Krishna Sainadh Kodati
Company Secretary and Compliance Officer

Encl as above



To,

Date: 29.05.2026

**BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400001**

Dear Sir/Madam,


Sub: Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

I, **Krishna Kishore Kuchipudi**, Managing Director of **Jeevan Scientific Technology Limited** hereby declare that, the statutory Auditors of the Company, M/s. Pavuluri & Co., Chartered Accountants have issued an Audit Report (Standalone & Consolidated) with unmodified / unqualified opinion on Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and year ended 31st March, 2026.

This declaration is issued in compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you.

Yours sincerely,
For Jeevan Scientific Technology Limited


Krishna Kishore Kuchipudi
Managing Director
DIN: 00876539





Annexure I

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026]

Particulars	M/s. KP & Associates
Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment of M/s. KP & Associates, Chartered Accountants as Internal Auditor of the Company.
Date of appointment & Terms of appointment	Date of appointment: 29.05.2026 Terms of appointment: For the Financial Year 2026-27.
Brief Profile	M/s. KP & Associates, Chartered Accountants, having over 15 years of experience in the areas of Audit and Assurance, Direct and indirect Taxation, Financial Services, Corporate Advisory, Corporate Laws and Secretarial Practice, etc.
Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

**Annexure II**

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.]

S. No	Particulars	Details
1.	Brief details of options granted	Grant of 4,80,000 options to eligible employees. Effective grant date being 29.05.2026.
2.	whether the scheme is in terms of SEBI (SBEB) Regulations, 2021 (if applicable)	JSTL Employee Stock Option Scheme - 2016 has been formulated and adopted by the Company in terms of the Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014.
3.	Total number of shares covered by these options	4,80,000 Equity Shares of face value Rs. 10/- (Rupees Ten Only) each. (Each Option is convertible into one Equity Share of the Company).
4.	Pricing Formula	As per the JSTL Employee Stock Option Scheme - 2016 ("Scheme"), the exercise price of the Shares will be decided by NRC.
5.	Options Vested	The said options shall vest, as under:- <ul style="list-style-type: none">• At the end of 1st year from the grant date - 25% of options granted.• At the end of 2nd year from the grant date - 25% of options granted.• At the end of 3rd year from the grant date - 25% of options granted.• At the end of 4th year from the grant date - 25% of options granted.
6.	Time within which option may be exercised	The exercise period shall be 1 – 5 years from the date of last vesting
7.	Options exercised	Not applicable
8.	Money realized by exercise of Options	Not Applicable



9.	The total number of Shares arising as a result of exercise of Option	Not Applicable
10.	Options lapsed	Not Applicable
11.	Variation in terms of Options	Not Applicable
12.	Brief details of significant terms	<p>The Scheme is administered by the Nomination and Remuneration Committee. The grant of Options is based upon the eligibility criteria as mentioned in the Scheme.</p> <p>a) The granted Options, once vested shall entitle the Option holder to acquire equal number of Equity Shares, upon payment of exercise price and applicable taxes in accordance with terms and conditions of the Scheme.</p> <p>b) The granted Options shall vest within minimum period of 1 year and maximum period of 5 years from the date of grant.</p> <p>c) The Exercise Price of the Options granted to an Eligible Employee shall be determined by the Nomination and Remuneration Committee subject to conforming to applicable accounting policies. Provided, however, the Exercise Price shall in no event be less than the face value of the Shares.</p>
13.	Subsequent changes or cancellation or exercise of such Options	Not Applicable
14.	Diluted earnings per share pursuant to the issue of equity shares on exercise of Options	Not Applicable



Annexure-III

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026]

Sl. No	Particulars	Details
1.	Brief details of options granted	The present instance is for allotment of Equity shares upon exercise of 1,61,250 options under JSTL- ESOP Scheme 2016.
2.	Whether the scheme is in terms of SEBI (SBE) Regulations, 2021 (if applicable);	Yes
3.	Total number of shares covered by these options	25,00,000 Equity Shares are covered under this scheme.
4.	Pricing formula	Face Value
5.	Options vested	Under the scheme 7,10,250 options have vested.
6.	Time within which option may be exercised	5 Years from the date of vesting.
7.	Options exercised	1,61,250
8.	Money realized by exercise of options	16,12,500
9.	The total number of shares arising as a result of exercise of option	1,61,250
10.	Options lapsed	Options which are lapsed, will be added back to the ESOP poll account.
11.	Variation of terms of options	Not Applicable
12.	Brief details of significant terms	All vested options shall be respectively exercised in one or more tranches within a period of 5 years from the respective dates of vesting, failing which the options shall lapse, which will be added back to the ESOP poll account.
13.	Subsequent changes or cancellation or exercise of such options	Not Applicable
14.	Diluted earnings per share pursuant to issue of equity shares on exercise of options.	Not Applicable

**Annexure-IV****Details under Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021**

Sl. No	Particulars	Details
1.	Company name and address of Registered Office	Name of the Company: Jeevan Scientific Technology Limited Address: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Hyderabad – 500008, Telangana.
2.	Name of the Stock Exchanges on which the company's shares are listed	BSE Limited
3.	Filing date of the statement referred in regulation 10(b) of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 with the recognised Stock Exchange	The statement referred to Regulation 10(b) of SEBI (Share Based Employee Benefits) Regulations, 2014 was filed with BSE Limited on 08.12.2016.
4.	Filing Number, if any	Case No. 47136
5.	Title of the Scheme pursuant to which shares are issued, if any	JSTL- ESOP Scheme 2016
6.	Kind of security to be listed	Equity Shares
7.	Par value of the shares	Rs.10/- per share
8.	Date of issue of shares	29 th May, 2026 (Date of allotment on exercise)
9.	Number of shares issued	1,61,250 Equity Shares
10.	Share Certificate No., if applicable	Not Applicable
11.	Distinctive number of the share, if applicable	19918966-20080215
12.	ISIN Number of the shares if issued in Demat	INE237B01018
13.	Exercise price per share	Rs.10/-
14.	Premium per share	--



15.	Total issued shares after this issue	2,00,80,215 Equity Shares
16.	Total issued share capital after this issue	Rs. 20,08,02,150/-
17.	Details of any lock in on the shares	Not Applicable
18.	Date of expiry of lock-in	Not Applicable
19.	Whether shares are identical in all respects to existing shares. If not, when will they become identical	Yes, the shares rank pari passu with the existing shares
20.	Details of listing fees, if payable	Not Applicable

Krishna Sainadh Kodati
Company Secretary and compliance Officer

Date: 29.05.2026
Place: Hyderabad

Jeevan Scientific Technology Limited
 CIN:L72200TG1999PLC031016
 Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.
Statement of Standalone Audited Financial Results for the Quarter and Year Ended 31st March 2026
 (All Amounts in Indian rupees lakhs, except share data and where otherwise stated)

Particulars	Quarter Ended				Year Ended	
	31 March 2026	31 December 2025	31 March 2025	31 March 2026	31 March 2025	
	Audited	Unaudited	Audited	Audited	Audited	
I Revenue from operations						
(a) Net sales/Income from operations	1,837.73	1,690.66	892.48	5,393.13	4,360.99	
II Total revenue from operation	1,837.73	1,690.66	892.48	5,393.13	4,360.99	
Other Income	36.62	18.06	14.10	118.78	62.92	
III Total income (I+II)	1,874.35	1,708.72	906.58	5,511.91	4,423.90	
IV Expenses						
(a) Cost of materials consumed	149.06	138.17	112.19	443.27	365.10	
(b) Changes in inventories or finished goods, work-in-progress and stock-in-trade						
(c) Employee benefits expense	495.42	456.77	461.46	1,799.40	1,585.30	
(d) Finance costs	25.40	38.17	35.37	137.77	103.56	
(e) Depreciation and Amortization expense	135.90	135.24	152.89	565.45	528.91	
(f) Other Expenses	845.64	630.80	409.75	2,302.09	1,783.97	
Total Expenses (IV)	1,651.42	1,399.15	1,171.66	5,247.97	4,346.86	
V Profit/(Loss) before Tax (III-IV)	222.93	309.57	(265.08)	263.94	77.05	
VI Tax Expenses						
(a) Current tax	38.16	6.40	(41.35)	44.56	12.02	
(b) MAT Credit / (Entitlement)	(27.51)	(6.40)	41.35	(33.91)	(12.02)	
(c) Deferred tax	52.80	79.51	(131.37)	88.28	3.48	
Total tax expense	63.45	79.51	(131.37)	98.93	3.48	
VII Profit/(Loss) for the period/year (V-VI)	159.48	230.06	(133.71)	165.01	73.57	
VIII Other Comprehensive Income						
A (i) Items that will not be reclassified subsequently to profit or loss	6.05	-	2.46	17.82	(1.37)	
(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss	-	-	-	-	-	
B (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	



R. Venkateshwar Rao

	(ii) Income tax relating to items that will be reclassified to profit or loss								
	Total other comprehensive income/(loss) for the period	6.05	-	2.46	17.82	(1.37)			
IX	Total Comprehensive Income for the period (VII+VIII)	165.53	230.06	(131.25)	182.83	72.20			
X	Paid Up equity share capital (Face value of Rs. 10/- each)								
XI	Other equity	1,991.90	1,583.40	1,583.40	1,991.90	1,583.40			
XII	Earnings per equity share (of Rs. 10/- each) (not annualized for the quarters)						5,337.88	3,508.41	
	a) Basic	0.80	1.45	(0.86)	0.83	0.47			
	b) Diluted	0.95	1.45	(0.83)	0.98	0.46			

Notes to the Audited financial results

- The above standalone financial results of Jeevan Scientific Technology Limited ("the Company") has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 29, 2026. The results for the quarter and year ended March 31, 2026 has been audited by our statutory auditors. The statutory auditors of the Company have expressed an unmodified opinion on the financial results for the quarter and year ended March 31, 2026.
- These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- The company operates in one reportable business segment i.e. Clinical Research Services. Hence segment reporting as per Ind AS 108 is not applicable.
- During the year ended March 31, 2026, the Company had allotted 40,85,000 fully paid equity shares of ₹ 10/- each to non-promoters, 30,00,000 partly paid convertible warrants to Promoter group and 5,00,000 partly paid convertible warrants to non-promoter category under the preferential allotment.
- Employee benefit expenses for the Quarter ending 31st March 2026 includes Rs.35.06 Lakhs towards ESOP Scheme 2016 provided as per " Ind AS 102 - Share Based Payments".
- On November 21, 2025, the Government of India notified four Labour Codes, effective immediately, replacing the existing 29 labour laws. In accordance with Ind AS 19 - Employee benefits, changes to employee benefit plans arising from legislative amendments are treated as plan amendments, requiring immediate recognition of past service cost in the Statement of Profit and Loss. This approach is consistent with the guidance issued by the Institute of Chartered Accountants of India.
- The figures for the current quarter and quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2026 and March 31, 2025, respectively and published year to date figures up to third quarter ended December 31, 2025 and December 31, 2024, respectively, which are subject to limited review by the statutory auditors.
- The results for the Quarter and Year ended 31st March 2026 are also available on website of BSE Limited and on the Company's website.

for Jeevan Scientific Technology Limited

Krishna Kishore Kuchipudi
Managing Director
(DIN:00876539)



R. Venkateswara Rao
Venkateswara Rao Ravipati
Chief Financial Officer

Place: Hyderabad,
Date: 29th May, 2026

Jeevan Scientific Technology Limited

CIN:L72200TG1999PLC031016


Registered Office:Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post,
Hyderabad-500008.

Statement of Standalone Audited Assets and Liabilities As at 31 March 2026


(Amount in Indian rupees lakhs, except share data and where otherwise stated)

	As at 31	As at 31 March
	March 2026	2025
	Audited	Audited
Assets		
(1)Non-current Assets		
a) Property, plant and equipment	2,092.93	1,757.43
b) Other intangible assets	705.94	686.57
c) Capital Work in Progress	-	-
d) Right of use assets	292.79	427.72
e) Financial Assets		
i)Investments	500.00	200.00
ii)Other financial assets	68.94	63.17
f) Other non current assets	1,207.54	857.54
g) Deferred tax asset (net)	-	77.63
	4,868.13	4,070.06
(2)Current Assets		
a) Inventories	161.41	93.35
b) Financial Assets		
i) Trade receivables	1,853.38	1,439.09
ii) Cash and cash equivalents	946.79	20.59
iii)Other financial assets	860.05	661.80
c) Current tax assets (net)	609.95	338.61
d) Other current assets	625.56	438.01
	5,057.13	2,991.45
TOTAL ASSETS	9,925.27	7,061.51
Equity and Liabilities		
Equity		
a) Equity Share Capital	1,991.90	1,583.40
b) Other Equity	5,337.88	3,508.41
	7,329.77	5,091.81
Liabilities		
(1)Non-current Liabilities		
a) Financial liabilities		
(i) Borrowings	635.10	602.21
(ii) Lease liabilities	244.44	335.76
b) Provisions	73.88	55.84
c) Deferred tax Liability (net)	10.65	
	964.07	993.81
(2)Current Liabilities		
a)Financial liabilities		
i) Borrowings	522.93	222.49
ii) Lease liabilities	91.32	126.86
iii) Trade payables		
(a) Total outstanding dues of micro, small and medium enterprises	193.30	99.39
(b) Total Outstanding dues of creditors other than micro, small and medium enterprises	330.82	174.08
iv) Other financial liabilities	126.27	106.74
b) Other current liabilities	319.78	232.67
c) Provisions	47.01	13.68
d) Current tax liabilities (net)		
	1,631.43	975.90
TOTAL EQUITY AND LIABILITIES	9,925.27	7,061.51

Place: Hyderabad.
Date: 29th May, 2026


Krishna Kishore Kuchipudi
Managing Director
(DIN:00876539)




Venkateswara Rao ravipati
Chief Financial Officer

Jeevan Scientific Technology Limited

CIN:L72200TG1999PLC031016

Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.

Statement of Standalone Audited Cash Flows for the Year Ended 31st March, 2026

(Amount in Indian rupees lakhs, except share data and where otherwise stated)

S.No	Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
A.	Cash flow from operating activities		
	Net Profit/(loss) before tax	263.94	77.05
	Adjustments for:		
	Depreciation and amortisation expenses	565.45	528.91
	Dividend received	(11.56)	(5.03)
	Interest received	(32.14)	(41.17)
	Fair value (gain)/loss on financial assets measured at amortized cost, net	(3.61)	(3.60)
	Share based payments to employees	71.14	104.09
	Net foreign exchange loss/(gain)	(45.38)	2.36
	Finance cost	128.09	84.24
	Operating profit before working capital changes	935.92	746.85
	Changes in Working Capital		
	Inventories	(68.07)	7.45
	Trade receivables	(368.90)	(248.43)
	Current and non current financial assets	(200.40)	(264.52)
	Other current and non current assets	(435.62)	(96.03)
	Trade payables	250.64	87.11
	Other financial liabilities	19.54	2.64
	Other liabilities	87.11	34.65
	Provisions	24.63	14.11
	Cash generated from operations before Tax	244.85	283.83
	Taxes Paid	10.65	12.02
	Net cash from operating activity	255.50	295.85
B.	Cash flow from investing activities		
	Purchase of property, plant and equipment including capital advances and capital creditors	(1,135.39)	(1,030.32)
	Investment in subsidiaries	(300.00)	
	Dividend Received	11.56	5.03
	Movement in other bank balances		
	Interest Received	32.14	41.17
	Net cash used in investing activity	(1,391.68)	(984.11)
C.	Cash flow from financing activity		
	Repayment of non current borrowings	74.84	424.18
	Repayment of current borrowings	258.51	(23.41)
	Interest paid	(128.09)	(84.24)
	Dividend paid		
	Proceeds from issuance of Equity Shares (ESOPS Exercise)	1,984.00	35.38
	Repayment of principle portion of lease liability	(126.86)	305.94
	Net cash generated in financing activity	2,062.40	657.85
	Net increase in cash and cash equivalents (A+B+C)	926.21	(30.42)
	Cash and cash equivalents at the beginning of the year/period	20.59	51.01
	Cash and cash equivalents at the end of the year/period	946.79	20.59

Place: Hyderabad
Date: 29th May 2026

Krishna Kishore Kuchipudi
Krishna Kishore Kuchipudi
Managing Director
(DIN:00876539)



R. Venkateswara Rao
Venkateswara Rao Ravipati
Chief Financial Officer



**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF THE STANDALONE
FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF JEEVAN SCIENTIFIC TECHNOLOGY
LIMITED**

Opinion

We have audited the accompanying Statement of Standalone Financial Results of JEEVAN SCIENTIFIC TECHNOLOGY LIMITED (the "Company"), for the quarter and year ended March 31, 2026 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

a. is presented in accordance with the requirements of Regulation 33 and 52 of the Listing Regulations;

and

b. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards ("Ind AS") and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the quarter and year then ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SA's) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the quarter and year ended March 31, 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Standalone Financial Results

This Statement, which includes the Standalone financial results is the responsibility of the Company's Board of Directors, and has been approved by them for the issuance. The Statement has been compiled from the related audited Interim condensed standalone financial statements for the three months and year ended March 31, 2026.





This responsibility includes preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2026 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Ind AS, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors is responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve





PAVULURI & Co.

CHARTERED ACCOUNTANTS

Plot No.48, Flat No.301,
MICASA, Phase - I, Kavuri Hills,
Hyderabad - 500 033.

Ph : 040-2970 2638 / 2639

Email : mail@pavuluriandco.com

collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement

or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Standalone Financial Results, including the disclosures, and whether the Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Standalone Financial Results of the Company to express an opinion on the Standalone Financial Results.

Materiality is the magnitude of misstatements in the Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



Branches :

Flat No : 301, Block C, Green City Towers, Green City Township, Near Export Apparel Park, Visakhapatnam - 530049.

D.No.54-20/7-1B, Plot No.10, Road No.2, Kanakadurga GAZZETTED OFFICERS COLONY, GURUNANAK NAGAR, VIJAYAWADA-520007. Ph: 0866-2545418



PAVULURI & Co.

CHARTERED ACCOUNTANTS

Plot No.48, Flat No.301,
MICASA, Phase - I, Kavuri Hills,
Hyderabad - 500 033.

Ph : 040-2970 2638 / 2639

Email : mail@pavuluriandco.com

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For PAVULURI & CO

Chartered Accountants

(Firm's Registration No. 012194S)



CA . N. RAJESH

Partner

(Membership No.223169)

UDIN: 26223169ERAPOJ4197

Place: Hyderabad

Date: May 29, 2026

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

CIN:L72200TG1999PLC031016

Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.
Statement of Consolidated Audited Financial Results for the Quarter and Year Ended 31 March 2026

(All Amounts in Indian rupees lakhs, except share data and where otherwise stated)

Particulars	Quarter Ended		Year Ended	
	31 March 2026	31 December 2025	31 March 2025	31 March 2026
	Audited	Unaudited	Audited	Audited
Revenue from operations				
(a) Net sales/Income from operations	2,128.70	1,907.15	1,005.79	6,153.71
Total revenue from operation	2,128.70	1,907.15	1,005.79	6,153.71
Other Income	29.42	14.05	14.66	97.27
Total income (I+II)	2,158.12	1,921.20	1,020.45	6,250.98
IV Expenses				
(a) Cost of materials consumed	162.18	148.66	115.38	487.70
(b) Changes in Inventories of finished goods, work-in-progress and stock-in-trade				380.25
(c) Employee benefits expense	597.25	555.00	499.00	2,164.38
(d) Finance costs	40.82	54.27	54.60	203.94
(e) Depreciation and Amortization expense	160.84	160.00	177.08	664.24
(f) Other Expenses	939.02	680.66	429.69	2,519.98
Total Expenses (IV)	1,900.11	1,598.59	1,275.75	6,040.25
Profit/ (Loss) before Share of Profit/(Loss) from Associate (III-IV)	258.01	322.61	(255.30)	210.73
V				
Share of Profit/ (Loss) from Associate accounted using Equity Method	(1.53)	-	-	(1.53)
VII Profit/ (Loss) before Tax (V-VI)	256.48	322.61	(255.30)	209.20
VIII Tax expenses				
(a) Current tax	38.16	6.40	(41.35)	44.56
(b) MAT Credit / (Entitlement)	(27.51)	(6.40)	41.35	(33.91)
(c) Deferred tax	61.65	82.52	(129.08)	95.22
IX Profit/(Loss) for the period/year	184.18	240.09	(126.22)	103.33
X Other Comprehensive Income				
A (i) Items that will not be reclassified subsequently to profit or loss	6.05	-	2.46	17.82
(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss	-	-	-	-
B (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
Comprehensive Income for the period/year	6.05	-	2.46	17.82
				(1.37)

[Handwritten Signature]



R Venkateswarra Rao

XI	Total Comprehensive Income for the period /year	190.23	240.09	(123.76)	121.15	4.53
XII	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	1,991.90	1,583.40	1,583.40	1,991.90	1,583.40
XIII	Other equity excluding revaluation reserve			-	-	3,410.97
XIV	Earnings per Equity share					
	a) Basic (Amount in Rupees)	0.92	1.52	(0.81)	0.52	0.04
	b) Diluted (Amount in Rupees)	1.09	1.52	(0.79)	0.61	0.04
XV	Net profit attributable to: Owners of the company	160.74	142.28	(129.91)	115.08	13.43
	Non-Controlling interest	23.44	97.81	3.69	(11.75)	(7.53)
XVI	Other comprehensive income attributable to: Owners of the company	6.05	-	2.46	17.82	(1.37)
	Non-Controlling interest	-	-	-	-	-
XVII	Total comprehensive income attributable to: Owners of the company	166.79	142.28	(127.45)	132.90	12.06
	Non-Controlling interest	23.44	97.81	3.69	(11.75)	(7.53)

Notes to the Audited financial results

- The above consolidated financial results of Jeevan Scientific Technology Limited ("the Company"), including its subsidiaries (Collectively known as "the Group"), and its associates (as mentioned in note 3) has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 29, 2026. The results for the quarter and year ended March 31, 2026 has been audited by our statutory auditors. The statutory auditors of the Company have expressed an unmodified opinion on the financial results for the quarter and year ended March 31, 2026.
- These consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- The consolidated financial results include the results of the following entities:

Name of the Company	Country of Incorporation	Nature of relationship	% Holding
Nayas Laboratories Private Limited	India	Subsidiary	59.26%
Naya Pharma Private Limited	India	Associate	31.03%
- The Company has made capital contribution in Associate company Naya Pharma Private Limited during the quarter ended March 31, 2026.
- The company operates in one reportable business segment i.e. Clinical Research Services. Hence segment reporting as per Ind AS 108 is not applicable.
- During the year ended March 31, 2026, the Company had allotted 40,85,000 fully paid equity shares of ₹ 10/- each to non-promoters, 30,00,000 partly paid convertible warrants to Promoter group and 5,00,000 partly paid convertible warrants to non-promoter category under the preferential allotment.
- Employee benefit expenses for the Quarter ending 31st March 2026 includes Rs.35.06 Lakhs towards ESOP Scheme 2016 provided as per " Ind AS 102 - Share Based Payments".



R. Venkateswara Rao

- 8 On November 21, 2025, the Government of India notified four Labour Codes, effective immediately, replacing the existing 29 labour laws. In accordance with Ind AS 19 - Employee benefits, changes to employee benefit plans arising from legislative amendments are treated as plan amendments, requiring immediate recognition of past service cost in the Statement of Profit and Loss. This approach is consistent with the guidance issued by the Institute of Chartered Accountants of India.
- 9 The figures for the current quarter and quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2026 and March 31, 2025, respectively and published year to date figures up to third quarter ended December 31, 2025 and December 31, 2024, respectively, which are subject to limited review by the statutory auditors.
- 10 The results for the Quarter and Year ended 31st March 2026 are also available on website of BSE Limited and on the Company's website.

for Jeevan Scientific Technology Limited


Krishna Kishore Kuchipudi
Managing Director
(DIN:00876539)




R. Venkateswara Rao
Chief Financial Officer

Place: Hyderabad.
Date: 29th May, 2026

Jeevan Scientific Technology Limited
CIN:L72200TG1999PLC031016

Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post,
Hyderabad-500008.

Statement of Consolidated Audited Assets and Liabilities As at 31st March, 2026


(Amount in Indian rupees lakhs, except share data and where otherwise stated)

Particulars	As at 31 March 2026	As at 31 March 2025
	Audited	Audited
Assets		
(1) Non-current Assets		
a) Property, plant and equipment	2,543.63	2,270.50
b) Other intangible assets	705.94	686.57
c) Capital work in progress	471.05	471.05
d) Right of use assets	358.82	497.50
e) Financial Assets		
i) Investments	298.47	
ii) Other financial assets	86.26	78.24
f) Other non current assets	1,207.54	857.54
g) Deferred tax asset (net)	-	91.89
	5,671.71	4,953.30
(2) Current Assets		
a) Inventories	302.74	161.82
b) Financial Assets		
i) Trade receivables	2,069.31	1,594.22
ii) Cash and cash equivalents	950.55	24.23
iii) Other financial assets	213.64	155.00
c) Current tax assets (Net)	624.30	343.11
d) Other current assets	826.47	597.37
	4,987.00	2,875.75
TOTAL ASSETS	10,658.72	7,829.05
Equity and Liabilities		
Equity		
a) Equity share capital	1,991.90	1,583.40
b) Other equity	5,202.34	3,410.97
Total equity	7,194.23	4,994.36
Non controlling interest	100.75	12.75
	7,294.98	5,007.12
Liabilities		
(1) Non-current Liabilities		
a) Financial liabilities		
(i) Borrowings	1,009.92	1,173.03
(ii) Lease liabilities	287.21	386.01
b) Provisions	73.88	55.84
c) Deferred tax Liability (net)	3.33	
	1,374.34	1,614.88
(2) Current Liabilities		
a) Financial Liabilities		
i) Borrowings	705.98	341.30
ii) Lease liabilities	125.31	157.64
iii) Trade payables		
(a) Total outstanding dues of micro, small and medium enterprises	222.12	40.79
(b) Total outstanding dues of Creditors other than micro, small and medium enterprises	390.64	276.91
iv) Other financial liabilities	133.02	113.17
v) Other Financial Creditors		
b) Other current liabilities	365.31	263.56
c) Provisions	47.01	13.68
	1,989.39	1,207.05
TOTAL EQUITY AND LIABILITIES	10,658.72	7,829.05

Place: Hyderabad
Date: 29th May 2026

Krishna Kishore Kuchipudi
Managing Director
(DIN:00876539)

R. Venkateswara Rao
Venkateswara Rao Ravipati
Chief Financial Officer



Jeevan Scientific Technology Limited

CIN:L72200TG1999PLC031016

Registered Office:Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post,
Hyderabad-500008.

Statement of Consolidated Audited Cash flow for the year ended 31st March, 2026

(Amount in Indian rupees lakhs, except share data and where otherwise stated)

S.No	Particulars	As at 31 March 2026	As at 31 March 2025
A.	Cash flow from operating activities		
	Net Profit before tax and extraordinary items	210.73	5.07
	Adjustments for:		
	Depreciation	664.24	625.16
	Adjustments on account of fairvalue measurement of lease deposits	(0.91)	-
	Dividend Received	(11.56)	(5.03)
	Remeasurement Gain/Loss on Defined Benefit plans	17.82	(1.37)
	Interest Received	(3.86)	(41.38)
	Foreign exchange loss/(gain)	-	2.36
	Share based payments to employees	71.13	104.09
	Interest paid	203.94	176.09
	Operating profit before working capital changes	1,151.53	864.98
	Changes in Working Capital		
	Inventories	(140.92)	(52.83)
	Trade receivables	(475.08)	(367.46)
	Current and non current financial assets	(58.64)	143.35
	Other current and non current assets	(860.29)	185.95
	Trade payables	295.05	102.99
	Other financial liabilities	(12.48)	56.55
	Other liabilities	101.75	46.25
	Provisions	51.37	27.50
	Cash generated from operations before Tax	52.29	1,007.29
	Tax Paid	10.65	
	Net cash from operating activity	41.64	1,007.29
B.	Cash flow from investing activities		
	Purchase of fixed assets	(818.06)	(1,603.14)
	investments in fixed deposits and margin money deposits with banks	(8.02)	(5.25)
	Change in Non controlling interest	112.50	
	Dividend Received	11.56	5.03
	Acquisition of a subsidiary, net of cash acquired	(300.00)	
	Interest Received	3.86	41.38
	Net cash used in investing activity	(998.16)	(1,561.99)
C.	Cash flow from financing activity		
	Proceeds from non current borrowings	(163.11)	368.08
	Repayment of current borrowings	364.68	68.00
	Interest paid	(203.94)	(176.09)
	Dividend paid		
	Proceeds from issuance of Equity Shares	1,984.00	35.38
	Repayment of Lease Liability	(98.80)	229.11
	Proceeds from share based paymnets		
	Net cash generated in financing activity	1,882.84	524.48
	Net increase in cash and cash equivalents (A+B+C)	926.32	(30.22)
	Cash and cash equivalents at the beginning of the year/period	24.23	54.45
	Cash and cash equivalents at the end of the year/period	950.55	24.23

Krishna Kishore Kuchipudi
Krishna Kishore Kuchipudi

Managing Director
(DIN:00876539)



R. Venkateswara Rao
Venkateswara Rao Ravipati
Chief Financial Officer

Place: Hyderabad
Date: 29th May 2026



INDEPENDENT AUDITOR'S REPORT ON AUDIT OF CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Opinion

We have audited the accompanying Statement of Consolidated Financial Results of JEEVAN SCIENTIFIC TECHNOLOGY LIMITED (the "Company") and its subsidiaries (the Company and its subsidiaries together referred to as the "Group"), for the quarter and year ended March 31, 2026 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

(i) includes the results of the subsidiary M/s Nayas Laboratories Private Limited; and share of loss from Associate M/s Naya Pharma Private Limited

(ii) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations;

and

(iii) gives a true and fair view in conformity with the recognition and measurement laid down in the Indian Accounting Standards ("Ind AS") and other accounting principles generally accepted in India of the consolidated net profit and consolidated total comprehensive income and other financial information of the Group for the quarter and year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SA" s) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Consolidated Financial Results

This Statement which includes Consolidated financial results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The





Statement has been compiled from the audited interim condensed consolidated financial statements for the three month and year ended March 31, 2026. This responsibility includes preparation and presentation of the Consolidated Financial Results that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Ind AS, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Company, as aforesaid.


In preparing the Consolidated Financial Results, the respective Boards of Directors of the companies included in the Group are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Boards of Directors either intend to liquidate their respective entities or to cease operations, or have no realistic alternative but to do so.

The respective Boards of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results as a whole, are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:



Branches :

Flat No : 301, Block C, Green City Towers, Green City Township, Near Export Apparel Park, Visakhapatnam - 530049.
D.No.54-20/7-1B, Plot No.10, Road No.2, Kanakadurga GAZZETED Officers colony, Gurunanak Nagar, Vijayawada-520007. Ph: 0866-2545418



PAVULURI & Co.

CHARTERED ACCOUNTANTS

Plot No.48, Flat No.301,
MICASA, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639
Email : mail@pavuluriandco.com

- Identify and assess the risks of material misstatement of the Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 and 52 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Financial Results, including the disclosures, and whether the Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities within the Group to express an opinion on the Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Consolidated Financial Results of which we are the independent auditors.

Materiality is the magnitude of misstatements in the Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Consolidated Financial Results may be influenced. We consider



Branches :

Flat No : 301, Block C, Green City Towers, Green City Township, Near Export Apparel Park, Visakhapatnam - 530049.
D.No.54-20/7-1B, Plot No.10, Road No.2, Kanakadurga Gas Reservoir Officers colony, Gurunanak Nagar, Vijayawada-520007. Ph: 0866-2545418



PAVULURI & Co.

CHARTERED ACCOUNTANTS

Plot No.48, Flat No.301,
MICASA, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639
Email : mail@pavuluriandco.com

quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Consolidated Financial Results.

We communicate with those charged with governance of the Company and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For PAVULURI & CO

Chartered Accountants

(Firm's Registration No. 012194S)



CA . N. RAJESH

Partner

(Membership No.223169)

UDIN: 26223169KNYUII7099

Place: Hyderabad

Date: May 29, 2026